• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Pfizer

Pfizer

PACE International Fixed Income C PWFCX 2 Star

Last Price$9.78Day Change (%)0.41%
Open Price$9.78Day Change ($)0.04
Day Range9.78–9.7852-Week Range9.68–10.98

As of Thu 12/07/2016 | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Pfizer Announces Expiration And Results Of Tender Offer For Any And All Of Its 6.200% Senior Notes Due March 15, 2019

    Pfizer Announces Expiration And Results Of Tender Offer For Any And All Of Its 6.200% Senior Notes Due March 15, 2019

  2. What's News: Business & Finance -- WSJ

    What's News: Business & Finance -- WSJ

  3. Stocks Advance After Wall Street Highs -- 2nd Update

    Stocks Advance After Wall Street Highs -- 2nd Update

  4. Xerox Adds More Directors to its Board

    Xerox Adds More Directors to its Board

  5. New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

    New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

  6. Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting

    Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting

  7. Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting

    Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting

  8. UPDATE: Share buybacks will rise 30% to $780 billion next year

    UPDATE: Share buybacks will rise 30% to $780 billion next year

  9. UPDATE: Share buybacks will rise 30% to $780 billion next year, says Goldman Sachs

    UPDATE: Share buybacks will rise 30% to $780 billion next year, says Goldman Sachs

  10. Biotech takes Trump presidency as a green light -- and end to drug price worries

    Biotech takes Trump presidency as a green light -- and end to drug price worries

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.